Syneos Health (NASDAQ:SYNH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina. “

How to Become a New Pot Stock Millionaire

SYNH has been the subject of several other reports. Barclays reissued an “equal weight” rating and issued a $43.00 target price (up from $40.00) on shares of Syneos Health in a report on Thursday, March 1st. Credit Suisse Group reduced their target price on Syneos Health from $68.00 to $54.00 and set an “outperform” rating for the company in a report on Tuesday, November 14th. Robert W. Baird set a $46.00 target price on Syneos Health and gave the company a “buy” rating in a report on Thursday, November 16th. BidaskClub raised Syneos Health from a “hold” rating to a “buy” rating in a report on Wednesday, January 3rd. Finally, Wells Fargo & Co raised Syneos Health from a “market perform” rating to an “outperform” rating in a report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $49.78.

Syneos Health (SYNH) traded down $0.40 during trading on Wednesday, hitting $40.25. The stock had a trading volume of 128,918 shares, compared to its average volume of 1,088,051. Syneos Health has a fifty-two week low of $31.10 and a fifty-two week high of $61.10. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.23 and a quick ratio of 1.23. The stock has a market cap of $4,570.33, a P/E ratio of -29.00, a P/E/G ratio of 1.30 and a beta of 0.65.

In related news, CAO Christopher L. Gaenzle sold 1,470 shares of the business’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $41.00, for a total value of $60,270.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.24% of the company’s stock.

A number of hedge funds have recently modified their holdings of SYNH. Geode Capital Management LLC acquired a new position in Syneos Health during the 4th quarter worth approximately $23,570,000. Municipal Employees Retirement System of Michigan acquired a new position in Syneos Health during the 4th quarter worth approximately $741,000. Finally, Globeflex Capital L P acquired a new position in Syneos Health during the 4th quarter worth approximately $210,000.

WARNING: “Syneos Health (SYNH) Downgraded by Zacks Investment Research to Hold” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.dailypolitical.com/2018/03/14/syneos-health-synh-downgraded-by-zacks-investment-research-to-hold.html.

Syneos Health Company Profile

Syneos Health, Inc, formerly INC Research Holdings, Inc, is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services.

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.